<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098198</url>
  </required_header>
  <id_info>
    <org_study_id>BioMetabol</org_study_id>
    <nct_id>NCT04098198</nct_id>
  </id_info>
  <brief_title>Biomarkers for Inborn Errors of Metabolism</brief_title>
  <acronym>BioMetabol</acronym>
  <official_title>Biomarkers for Inborn Errors of Metabolism: An International, Multicenter, Observational, Longitudinal Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centogene AG Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, observational, longitudinal study to identify or monitor Inborn
      Error of Metabolism disease biomarkers and to explore the clinical robustness, specificity,
      and long-term variability of these biomarkers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inborn Errors of Metabolism (IEM) are a large group of congenital metabolic disorders,
      resulting from the absence or abnormality of an enzyme or its cofactor and leading to either
      accumulation or deficiency of a specific metabolite. More than 800 IEM have been described in
      the literature, with a widely accepted classification focusing on the main substrate which is
      affected.

      Clinical phenotypes of IEM are broad and often non-specific, mimicking more common
      conditions, and the onset of symptoms can occur at any age, from fetus to adult. Peroxisomal
      and lysosomal storage disorders, for example, often have characteristic clinical features and
      permanent, progressive symptoms that are independent of triggering events (e.g. anemia,
      thrombocytopenia, and hepatomegaly in a child of Ashkenazi-Jewish ancestry is suggestive of
      Gaucher disease) 6. More common findings include hypoketotic hypoglycemia, lactic acidosis,
      metabolic acidosis, ketosis, hyperammonemia, or other metabolic acidosis in combination with
      hyperammonemia.

      The goal of treatment for participants with IEM are the prevention of further accumulation of
      harmful substances, correction of metabolic abnormalities, and elimination of toxic
      metabolites. Most participants suffering for rare metabolic diseases start with very severe
      phenotypes and with rapid progression of the disease that often leads to irreversible damage
      of their organs. A quick diagnosis is necessary for urgent treatment.

      Biomarkers serve as measurable indicators of normal biological or pathological processes.
      They are typically directly linked to genetic variants in specific genes and can predict,
      diagnose, monitor and assess the severity of a disease.

      CENTOGENE has an outstanding experience regarding the investigation and development of
      biomarkers for IEM. Given the large amount of participants CENTOGENE is facing and
      diagnosing, it has a big repertoire of samples to use for the biomarker characterization.
      This led for example to the identification of Lyso-Gb1 as a novel biomarker for Gaucher
      disease orLyso-SM509 for Niemann-Pick Disease. The established workflows and gained knowledge
      for the biomarker development at CENTOGENE will enhance the search for new biomarkers of
      other IEM.

      It is the goal of this study to identify, validate, and monitor biochemical markers from
      affected participants for Inborn Errors of Metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of biomarkers for Inborn Errors of Metabolism</measure>
    <time_frame>2 years</time_frame>
    <description>All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploring the clinical robustness, specificity, and long-term variability of biomarkers for Inborn Errors of Metabolism</measure>
    <time_frame>2 years</time_frame>
    <description>Samples will be analyzed for the identified biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Inborn Errors of Metabolism</condition>
  <condition>Biomarker</condition>
  <arm_group>
    <arm_group_label>Participants with an Inborn Error of Metabolism</arm_group_label>
    <description>Participants diagnosed with an Inborn Error of Metabolism aged between 2 months to 50 years</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (CentocardÂ®)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with an Inborn Error of Metabolism
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent is obtained from the participant or from their parent/legal guardian,
             before any study related procedures

          -  The participant aged between 2 months old and 50 years old

          -  The diagnosis of an Inborn Error of Metabolism is genetically confirmed

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  The participant is younger than 2 months old or older than 50 years old

          -  The diagnosis of an Inborn Error of Metabolism (IEM) is not genetically confirmed

          -  Previously enrolled in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centogene AG Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volha Skrahina, PhD</last_name>
    <phone>+49 (0)38180113594</phone>
    <email>Volha.Skrahina@centogene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omnia El Rashidy, MD</last_name>
      <phone>+20 (0)1222164876</phone>
      <email>omniarashidy@hotmail.com</email>
    </contact>
    <contact_backup>
      <phone>+20 (0)0224512900</phone>
      <email>draghdaz@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Omnia El Rashidy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Faculty of Medicine, Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hoda Tomoum, MD</last_name>
      <phone>+20 (0)0224156526</phone>
      <email>hodatomoum@gmail.com</email>
    </contact>
    <contact_backup>
      <email>mennahshata@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hoda Tomoum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences</name>
      <address>
        <city>Kerola</city>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheela Nampoothiri, MD</last_name>
      <phone>+91 (0)9447978222</phone>
      <email>sheelanampoothiri@aims.amrita.edu</email>
    </contact>
    <contact_backup>
      <phone>+91 (0)4842851234</phone>
    </contact_backup>
    <investigator>
      <last_name>Sheela Nampoothiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN)</name>
      <address>
        <city>Mumbai</city>
        <zip>400705</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Jalan, MD</last_name>
      <phone>+91 (0)2267910237</phone>
      <email>jalananil12@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anil Jalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's hospital, Vilnius University Hospital Santaros klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>O8406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rimante Cerkauskiene, MD</last_name>
      <phone>+37 (0)063009244</phone>
      <email>rimante.cerkauskiene@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rimante Cerkauskiene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children Hospital (gastroenterology department)</name>
      <address>
        <city>Rabat</city>
        <zip>10100</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nezha Mouane, MD</last_name>
      <phone>+21 (0)2537670294</phone>
      <email>nezhamouane@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Nezha Mouane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lady Ridgeway Hospital for Children</name>
      <address>
        <city>Colombo</city>
        <zip>00800</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eresha Jasinge, MD</last_name>
      <phone>+94 (0)712793328</phone>
      <email>eresha.jasinge@gmail.com</email>
    </contact>
    <contact_backup>
      <phone>+94 (0)714040998</phone>
      <email>chempath.lrh@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eresha Jasinge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>India</country>
    <country>Lithuania</country>
    <country>Morocco</country>
    <country>Sri Lanka</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Pakistan</country>
  </removed_countries>
  <link>
    <url>https://www.centogene.com/</url>
    <description>CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for Patients</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inborn Error of Metabolism</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

